---
title: AGI → ASI Pathways as Brown Biotech Strategic Context
created: 2026-06-16
updated: 2026-06-16
type: concept
tags: [concept, ai, methodology, strategic, hypothesis]
related: [agentic_patterns_brownbiotech_mapping, research-paper-format-gwas-first, bb-io-compass, oxphos-cancer-vulnerability]
sources: [raw/AGI_to_ASI_Genewein_DeepMind_2026_arXiv_2606_12683]
notion: 381f2735-33a4-8100-b13c-e6916dc7c35f
---

# AGI → ASI Pathways — Brown Biotech Strategic Context

> **한 줄:** Google DeepMind (Genewein, Legg, Hutter, Dafoe 등 14명)의 40+ page 정책 보고서 — AGI→ASI 전환 4 pathways + 6 frictions. Brown Biotech는 Pathway 3 (Recursive SI) + Pathway 4 (Multi-agent)에 직접 매핑 — ARP v27, bb-wiki, SoI가 contemporary example.

## 왜 BB가 이걸 신경써야 하는가

ASI 시대가 도래하면 "AI가 reasoning을 한다"는 positioning은 commodity화된다. BB의 SoI framing ("추론을 판다")은 단기 survival 전략이지 long-term moat가 아니다. Genewein et al. 2026은 4 pathways의 frictions & bottlenecks를 명시 → BB가 어느 pathway에 베팅해야 할지 우선순위 결정 가능.

## 4 Pathways — 요약 (Genewein et al. 2026, Section 5)

| # | Pathway | Main uncertainty | BB relevance |
|---|---|---|---|
| 1 | **Scaling (compute, models, data)** | "Spiky vs smooth progress? Diminishing returns?" | **약함** — BB는 foundation model 직접 학습 안 함 |
| 2 | **Algorithmic paradigm shifts** | "True paradigm shifts unpredictable" | **간접** — SoI reasoning layer로의 evolution이 생존 조건 |
| 3 | **Recursive self-improvement** | "Hyperbolic vs plateau — no historical precedent" | **직접** — Feature Factory, agent skill pack, CLAUDE.md patch |
| 4 | **Multi-agent coordination** | "Emergence poorly understood" | **직접** — ARP v27 3-engine, bb-wiki compound, SoI |

## 6 Bottlenecks (Genewein et al. 2026, Section 5.5)

| Friction | Description | BB implication |
|---|---|---|
| Data wall | High-quality training data 소진 | PRISM RAG의 fine-tuned base가 data wall 영향 받음 |
| Economic & natural resources | Gigawatt AI infra, rare earth | BB는 compute 의존도 낮음 → advantage |
| Neural paradigm insufficient | Current architecture 한계 | RAG-only BB는 도태 위험, reasoning layer로 evolution 필수 |
| Research gets harder | Low-hanging fruit 소진 | BB가 human expert dependency 큼 → "low-hanging"이 줄면 BB value 증가 |
| Abstraction barrier | AI가 human abstractions에 묶임 | BB Paid Brief는 human abstraction validation → moat |
| Deliberate slowdown | Regulation, rogue-actor | BB regulatory strategy 영향 (CLIA/CAP 등) |

## BB Pathway 매핑 — 상세

### Pathway 3 (Recursive SI) — **Highest BB relevance**

Genewein et al.의 4 RSI flavor:
- (a) Better code (architecture, optimizer) → BB: ARP v27 self-evolution
- (b) Hardware improvements → BB: N/A
- (c) Data improvements (AlphaZero-style distillation) → BB: PRISM RAG corpus curation
- (d) Division of labor → BB: 3-engine architecture

**Brown Biotech RSI instantiation:**
- `brown-biotech-feature-factory` skill = 4-agent pipeline (Planner → Coder → Tester → Reviewer)
- Agent skill pack = 매 세션 config patch = **memetic RSI** (문화적 RSI의 디지털화)
- CLAUDE.md corrections → immediate patch = **cultural RSI** (즉시 knowledge 흡수)
- Eugene Yan "compounding" = 명시적 recursive memetic loop

### Pathway 4 (Multi-agent) — **Highest BB relevance**

Genewein et al.의 multi-agent framing:
- List & Pettit 2011 "Group Agents" — fully automated corporations
- Tomašev 2025 "Virtual Agent Economies"
- Multi-Agent Scaling Laws (Leibo et al. 2019b)

**Brown Biotech multi-agent instantiation:**
- ARP v27 3-engine = cognitive division of labour (specialist engines)
- bb-wiki = distributed knowledge layer (raw → wiki → human judgment)
- SoI rollout = Group Agent at biotech reasoning layer (BB가 "the firm" = List & Pettit collective)
- Daily X-thread + Morning triage cron = specialized multi-agent workforce

### Pathway 2 (Paradigm shift) — **Medium BB relevance**

- 현재 paradigm: single LLM + RAG → 도태 위험
- Evolution target: SoI reasoning layer with multi-step planning + cross-validation
- 진짜 paradigm shift (spiking neurons, world model pretraining)는 예측 불가 → 단, RAG + reasoning의 hybrid는 near-term survival strategy

### Pathway 1 (Scaling) — **Weak BB relevance**

- BB는 foundation model 자체 학습 안 함 (frontier labs 의존)
- Test-time scaling (deep retrieval, multi-step reasoning)은 활용 가능
- "Naive scaling" = bad investment for BB

## 🎯 BB Positioning Implications

### Near-term (12-24 mo)
- **Pathway 4 강화** — ARP v27 multi-agent 구조가 most robust한 near-term investment
- **Pathway 3 활용** — 매 세션 config/skill patch workflow를 feature factory로 systematize
- **SoI messaging** — "reasoning layer on top of AI" = Group Agent framing, DeepMind-style positioning

### Medium-term (24-60 mo)
- **Pathway 2 대비** — paradigm shift 시 RAG-only 라면 도태. **Reasoning layer로의 evolution이 survival condition**
- **Pathway 1 추종** — foundation model 직접 학습은 BB scope 외, test-time compute는 강화

### Long-term (60+ mo)
- ASI 시대 BB positioning = "human-validated reasoning layer" — AI 판단을 human expert가 검증
- Paid Brief = 본질적으로 human-on-the-loop ASI artifact
- BB의 moat = human expert validation, not AI capability itself

---

## 4-섹션 판단 레이어

### 1. Source Quotes

> "This report investigates how AI itself might continue to develop in a post-AGI world along the continuum of machine intelligence. The endpoint of this continuum, Universal AI, is theoretically well understood, which provides some formal grounding for the main focus of this report: the transition from human-level AGI to artificial general superintelligence."
> — Genewein et al., *From AGI to ASI* (arXiv:2606.12683), Abstract

> "We first examine the continuation of scaling up effective compute, data, and model sizes... Next, we consider algorithmic paradigm shifts... We then discuss recursive improvement, where AI systems contribute to speeding up AI R&D... Finally, we explore multi-agent coordination, where superintelligence emerges as a collective property from the orchestrated or self-organized interaction of numerous AGI agents forming complex adaptive systems."
> — Genewein et al., 2026, Section 5 introduction (p.14)

> "Recursive (self-) improvement refers to the process of AI facilitating AI research & development, thereby leading to improved AI systems, that, in turn, can facilitate research progress even more, and so on. These recursive improvement dynamics could potentially lead to an 'explosive' transition from AGI to ASI."
> — Genewein et al., 2026, Section 5.3 (p.18)

> "A plausible pathway from AGI to ASI involves the (potentially emergent) coordination of many AGI agents into increasingly complex collective structures, analogous to how human general intelligence aggregates into superintelligent social and organisational entities."
> — Genewein et al., 2026, Section 5.4 (p.19)

### 2. My Interpretation

Genewein et al.의 진짜 contribution은 **pathway 분류의 깔끔함**입니다. 4 pathways는 mutually exclusive가 아니고 parallel하게 진행 (서로 다른 pace로). BB는 Pathway 1을 **도외시**하고, Pathway 3+4에 **집중 투자**해야 합니다.

**핵심 통찰:**
- **Pathway 3 (RSI) + Pathway 4 (Multi-agent)는 사실상 inseparable** — multi-agent collective이 recursive improvement를 통해 evolve하는 것이 Group Agent의 정의 (List & Pettit 2011)
- **Brown Biotech의 모든 운영 pattern (Feature Factory, bb-wiki, SoI, daily cron multi-agent workforce)이 이미 Pathway 3+4 instantiation** — 즉 BB는 ASI 시대에 이미 aligned된 운영 구조를 가짐
- **Strategic moat는 Pathway 2 (paradigm shift 적응력) + Pathway 1 (compute efficiency)** 이 아닌 **Pathway 3+4에서 "human-in-the-loop" 유지** — Paid Brief, human expert validation, judgment layer (bb-wiki 4-섹션)

**반대 입장 (caveat):** "Reasoning layer" positioning은 5년 안에 모든 AI 회사가 채택할 commodity framing이 될 가능성 큼. Long-term moat는 **domain expertise × human judgment × decision-ready delivery**의 3중 결합 — Paid Brief가 정확히 이거.

### 3. Open Questions

- **Q1.** BB의 Pathway 3 RSI loop가 현재 **의식적인 design인지 emergent한 outcome인지**? Feature factory + skill pack + CLAUDE.md patch가 "deliberate RSI"인가, 아니면 그냥 효율성 optimization의 부산물인가?
- **Q2.** **Pathway 4 (Multi-agent) BB 구현의 bottleneck은 무엇인가?** ARP v27 3-engine, bb-wiki, SoI, daily cron — 이들이 진짜 multi-agent로 작동하는지, 아니면 병렬 single-agent의 aggregate인지?
- **Q3.** **ASI 시대 BB의 customer가 누구인가?** Pharma BD? Investor? 내부 R&D team? "Human-validated reasoning"의 value가 누구에게 가장 큰가?
- **Q4.** **Pathway 2 (paradigm shift) 대비 전략** — RAG → reasoning layer evolution의 구체적 roadmap은? 6-month milestone로?
- **Q5.** **Notion page와 이 wiki page의 차이** — Notion은 executable (Active Projects, Status tracking), wiki는 conceptual (judgment layer). 이 역할 분담이 옳은가, 통합해야 하는가?
- **Q6.** **Long-term (60+ mo) "human-validated reasoning" moat이 sustainable한가?** ASI가 human expert 수준 도달하면 "validation"의 의미가 변질되지 않는가?
- **Q7.** **Shane Legg / Marcus Hutter / Allan Dafoe가 DeepMind policy 보고서를 쓴 의도** — 이건 research paper가 아니라 strategic positioning. BB는 이 framing을 차용해야 하는가, 아니면 anti-DeepMind positioning이 더 효과적인가?

### 4. Contradictions

- **vs. Eugene Yan "compounding"** — Yan은 human knowledge의 recursive accumulation을 강조 (cultural RSI). Genewein et al.은 AI R&D의 RSI를 강조. BB는 둘 다 instantiate하지만, **둘의 충돌 시점** (ASI가 human knowledge accumulation을 automate하는 시점)을 식별하지 않음.
- **vs. [[bb-io-compass]]** — BB-IO Compass는 human-clinical-judgment 기반 LDT (LKB1/KEAP1/SMARCA4 interpretation). ASI 시대에 AI가 자동 interpretation하면 BB-IO Compass의 moat 붕괴. **Paradigm shift (Pathway 2) 대비 안 됨**.
- **vs. ARP v27** — ARP v27의 "self-evolution"은 Pathway 3 (RSI) 의 narrow instantiation. Genewein et al.은 RSI가 **full intelligence explosion** 으로 확장될 수 있다고 주장. ARP v27의 self-evolution scope가 너무 좁을 가능성.
- **vs. Paid Briefs** — Paid Brief는 "human expert packaging"의 1-page compression. ASI가 "1-page brief"를 autonomous하게 생성하면 Paid Brief의 ₩2M-8M pricing 정당성 붕괴. **Pathway 1+2의 win이 BB pricing power를 약화**.
- **vs. [[scgpt_deep_analysis]]** — scGPT는 single-model foundation. Genewein et al. Pathway 2 (paradigm shift)는 post-foundation-model 시대. scGPT-class FM이 5년 안에 legacy가 될 가능성. BB는 single-model 의존도를 낮춰야 함.
- **vs. [[oxphos-cancer-vulnerability]]** — OXPHOS 페이지는 target-centric, multi-target evaluation. Genewein et al.은 pathway-centric, multi-pathway evaluation. **frame은 같지만 (multi-X) BB는 둘 다 유지해야**.

---

## 🔗 Cross-references

- **Notion page (executable):** https://app.notion.com/p/From-AGI-to-ASI-Genewein-et-al-DeepMind-2026-BB-Strategic-Context-381f273533a48100b13ce6916dc7c35f
- **Conceptual siblings:**
  - `[[agentic_patterns_brownbiotech_mapping]]` — multi-agent design pattern taxonomy
  - `[[bb-io-compass]]` — clinical product, Pathway 2 moat
  - `[[scgpt_deep_analysis]]` — single-FM dependency risk
  - `[[oxphos-cancer-vulnerability]]` — multi-target evaluation pattern
  - `[[research-paper-format-gwas-first]]` — 직전 페이퍼 format recipe
- **Workflow skills:**
  - `brown-biotech-feature-factory` — Pathway 3 instantiation
  - `arp-v24-prism-research-pipeline` — Pathway 4 + 2 instantiation
- **Raw source:** [[raw/AGI_to_ASI_Genewein_DeepMind_2026_arXiv_2606_12683]] (PDF at `/Users/ocm/.hermes/cache/documents/doc_5b4db191ad8d_2606.12683v1.pdf`)

---

> **Last updated:** 2026-06-16 | **Page scope:** Light F (BB strategic context only, 4-5KB) | **Status:** Synced to Notion + bb-wiki
